Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Wasserman

Showing results (231-240 of 259) with videos related to

Pageof 26
Sort By:
Journal of Clinical Immunology|March 7, 2012
Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiencyRichard L Wasserman, Joseph A Church, Mark Stein, et al.
Advances in Therapy|May 9, 2026
Clinical Evaluation of Pharmacokinetics, Efficacy, and Safety of a 10% Immunoglobulin in Primary Immunodeficiency Disease (CARES10 Study)Chaim M Roifman, Donald McNeil, William Lumry, et al.
IEEE Transactions on Biomedical Circuits and Systems|July 16, 2013
A Retinal Prosthesis Technology Based on CMOS Microelectronics and Microwire Glass ElectrodesD Scribner, L Johnson, P Skeath, et al.
Clinical Immunology (Orlando, Fla.)|November 17, 2009
Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and ImmunologyPierre L Yong, John Boyle, Mark Ballow, et al.
Journal of Oncology Practice|September 23, 2010
Benchmarks in clinical productivity: a national comprehensive cancer network surveyF Marc Stewart, Robert L Wasserman, Clara D Bloomfield, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 16, 2024
Age-Related Food Aversion and Anxiety Represent Primary Patient Barriers to Food Oral ImmunotherapyJordan Trevisonno, Carina Venter, Kaci Pickett-Nairne, et al.
The Journal of Allergy and Clinical Immunology|September 22, 2009
Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacksTimothy J Craig, Robyn J Levy, Richard L Wasserman, et al.
Journal of Clinical Immunology|May 18, 2006
Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiencyJoseph A Church, Heinz Leibl, Mark R Stein, et al.
Journal of Clinical Immunology|May 26, 2016
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary ImmunodeficiencyRichard L Wasserman, Isaac Melamed, Mark R Stein, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 3, 2010
Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacksJonathan A Bernstein, Bruce Ritchie, Robyn J Levy, et al.
Pageof 26

Showing results (231-240 of 259) with videos related to

Sort By:
Pageof 26
Journal of Clinical Immunology|March 7, 2012
Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiencyRichard L Wasserman, Joseph A Church, Mark Stein, et al.
Advances in Therapy|May 9, 2026
Clinical Evaluation of Pharmacokinetics, Efficacy, and Safety of a 10% Immunoglobulin in Primary Immunodeficiency Disease (CARES10 Study)Chaim M Roifman, Donald McNeil, William Lumry, et al.
IEEE Transactions on Biomedical Circuits and Systems|July 16, 2013
A Retinal Prosthesis Technology Based on CMOS Microelectronics and Microwire Glass ElectrodesD Scribner, L Johnson, P Skeath, et al.
Clinical Immunology (Orlando, Fla.)|November 17, 2009
Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and ImmunologyPierre L Yong, John Boyle, Mark Ballow, et al.
Journal of Oncology Practice|September 23, 2010
Benchmarks in clinical productivity: a national comprehensive cancer network surveyF Marc Stewart, Robert L Wasserman, Clara D Bloomfield, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 16, 2024
Age-Related Food Aversion and Anxiety Represent Primary Patient Barriers to Food Oral ImmunotherapyJordan Trevisonno, Carina Venter, Kaci Pickett-Nairne, et al.
The Journal of Allergy and Clinical Immunology|September 22, 2009
Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacksTimothy J Craig, Robyn J Levy, Richard L Wasserman, et al.
Journal of Clinical Immunology|May 18, 2006
Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiencyJoseph A Church, Heinz Leibl, Mark R Stein, et al.
Journal of Clinical Immunology|May 26, 2016
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary ImmunodeficiencyRichard L Wasserman, Isaac Melamed, Mark R Stein, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 3, 2010
Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacksJonathan A Bernstein, Bruce Ritchie, Robyn J Levy, et al.
Pageof 26